Research › Fact Sheets › REGN

REGENERON PHARMACEUTICALS, INC.

LISTEDNASDAQ

SYMBOLREGN

SIC2834

STATE OF INC.NY

FISCAL YEAR ENDSDecember 31

CIK872589

PHARMACEUTICAL PREPARATIONS · LARGE ACCELERATED FILER · 10 FISCAL YEARS OF SEC XBRL DATA, 2016–2025

Fiscal years labelled by the calendar year in which they end. Bars in $ billions; per-share figures as reported.

CAPITALIZATION 12/31/25

($ millions)	Amount	%
Total debt	1,986	6.0
Stockholders' equity	31,257	94.0
Total capitalization	33,243	100.0

93,955,110 shares outstanding at 13 July 2012 (cover page of the 10-Q filed 25 July 2012).

LONG-TERM DEBT 12/31/25

($ millions)	Amount
Long-term debt, noncurrent	1,986

CAPITAL STOCK 12/31/25

Treasury shares	33,700,000
Preferred stock ($ millions)	0
Outstanding at 7/13/12	93,955,110

DIVIDENDS DECLARED/PAID

Fiscal year	Per share $	Payout %
2025	–	–
2024	–	–
2023	–	–
2022	–	–
2021	–	–

HISTORY AND BUSINESS

HISTORY: Incorporated in New York.

BUSINESS: Classified by the SEC under Standard Industrial Classification 2834, Pharmaceutical Preparations. Large accelerated filer. Principal executive office: 777 Old Saw Mill River Road, Tarrytown, NY 10591. Fiscal year ends December 31. For a description of the business, see Item 1 of the latest 10-K.

CONSOLIDATED INCOME ACCOUNT, YEARS ENDED

($ millions)	12/31/25	12/31/24	12/31/23
Revenues	14,343	14,202	13,117
Research and development	5,850	5,132	4,439
Selling, general and administrative	2,700	2,954	2,631
Depreciation and amortization	544	483	421
Operating income	3,578	3,991	4,047
Interest expense	44	55	73
Income before income taxes	5,231	4,780	4,199
Income taxes	726	367	246
Net income	4,505	4,413	3,954
Earned per share, diluted ($)	41.48	38.34	34.77
Dividends per share ($)	–	–	–

CONSOLIDATED BALANCE SHEET

($ millions)	12/31/25	12/31/24
Cash and equivalents	3,118	2,488
Receivables, net	5,741	6,212
Inventories	3,201	3,087
Total current assets	18,022	18,661
Property, plant and equipment, net	5,120	4,600
Total assets	40,559	37,759
Total current liabilities	4,368	3,944
Long-term debt	1,986	1,984
Total liabilities	9,302	8,406
Stockholders' equity	31,257	29,354
Total liabilities and equity	40,559	37,759

TEN-YEAR STATISTICS: FISCAL YEARS ($ millions except per share)

Fiscal year ended	Revenues	Oper. income	Net income	Net margin %	EPS diluted $	Div. per share $	Oper. cash flow	Capital expend.	Free cash flow	Total assets	Total liabilities	Total debt	Stockholders' equity	ROE %	Debt / equity
12/31/25	14,343	3,578	4,505	31.4	41.48	–	4,979	898	4,080	40,559	9,302	1,986	31,257	14.4	0.06
12/31/24	14,202	3,991	4,413	31.1	38.34	–	4,420	756	3,665	37,759	8,406	1,984	29,354	15.0	0.07
12/31/23	13,117	4,047	3,954	30.1	34.77	–	4,594	719	3,875	33,080	7,107	1,983	25,973	15.2	0.08
12/31/22	12,173	4,739	4,338	35.6	38.22	–	5,015	590	4,425	29,214	6,550	1,981	22,664	19.1	0.09
12/31/21	16,072	8,947	8,075	50.2	71.97	–	7,081	552	6,529	25,435	6,666	1,980	18,769	43.0	0.11
12/31/20	8,497	3,577	3,513	41.3	30.52	–	2,618	615	2,004	17,163	6,138	1,978	11,025	31.9	0.18
12/31/19	6,558	2,210	2,116	32.3	18.46	–	2,430	430	2,000	14,805	3,716	0	11,090	19.1	0.00
12/31/18	5,146	2,534	2,444	47.5	21.29	–	2,195	383	1,812	11,734	2,977	–	8,757	27.9	–
12/31/17	5,872	2,080	1,198	20.4	10.34	–	1,307	273	1,034	8,764	2,620	–	6,144	19.5	–
12/31/16	4,860	1,331	896	18.4	7.70	–	1,486	512	974	6,973	2,524	–	4,449	20.1	–

Net margin = net income ÷ revenues; ROE = net income ÷ year-end stockholders’ equity; total debt = long-term debt including current maturities plus short-term borrowings/commercial paper, as tagged in XBRL; free cash flow = operating cash flow − purchases of property, plant and equipment; d = derived as total assets − total equity where the filing does not tag total liabilities; – = not reported in XBRL for that year.

REGISTRANT:

REGENERON PHARMACEUTICALS, INC.
CIK 872589 · EIN 13-3444607

PRINCIPAL OFFICE:

777 Old Saw Mill River Road, Tarrytown, NY 10591
Tel.: 9148477000

INCORPORATED:

New York

INDUSTRY (SEC SIC CODE):

2834 · Pharmaceutical Preparations

FILER STATUS:

Large accelerated filer

LATEST ANNUAL REPORT:

10-K for period ended 12/31/25, filed 4 February 2026

FORMER NAMES:

REGENERON PHARMACEUTICALS INC

RECENT FILINGS (ANNUAL REPORT REFERENCES BELOW):

10/6/26	8-K	period 10/1/26
9/30/26	8-K	period 9/24/26
7/30/26	10-Q	period 6/30/26
7/30/26	8-K	period 7/30/26
7/6/26	8-K	period 7/6/26
6/17/26	8-K	period 6/12/26
4/29/26	10-Q	period 3/31/26
4/29/26	8-K	period 4/29/26

Sources: SEC XBRL company facts (all financial figures) · SEC submissions (registrant, address, SIC, filings) · annual reports: 10-K FY2025 (filed 2/4/26) · 10-K FY2024 (filed 2/5/25) · 10-K FY2023 (filed 2/5/24) · 10-K FY2022 (filed 2/6/23) · 10-K FY2021 (filed 2/7/22) · 10-K FY2020 (filed 2/8/21) · 10-K FY2019 (filed 2/7/20) · 10-K FY2018 (filed 2/7/19). Values are the latest figures filed for each fiscal year (restated where a later 10-K restated them). Ratios and free cash flow are Pathos calculations from those figures. Retrieved 31 October 2026.